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The progress listed above has been made without resolution of the question of estrogen's effect on the rate of endometrial cancer in women who take estrogen. However, important progress has been made regarding the disease, itself It appears that there are two forms of endometrial cancer: a histologic low nuclear grade cancer, the endonietrioid type, and a high histologic grade cancer, usually termed serous or clear-cell. The former appears to be an extension of complex atypical hyperplasia, expresses steroid hormone receptors and is more common among hormone replacement therapy users. Endometrioid cancer has an extremely positive outcome since it metastasizes late and responds to hormone/antihormone treatment. On the other hand, serous/clear-celi endometrial cancers generally metastasize early, do not express estrogen receptors, and may not respond well to hormone therapy.
In light of the lack of an effect of the diagnosis of endomnetrial cancer ont mortality in cases from the epidemiologic studies, and a lack of studies showing estrogen to be a carcinogen, the question of whether endonmetrial cancer is caused by estrogen replacement therapy, especially at contemporary doses, is due for reconsideration. Since the diagnosis of early endometrioid endometnial cancer is subjective, because it depends solely upon the histologic picture, it seems that this question cannot be answered through the use of traditional morphologic methods. Rather, a marker of the change from complex atypia to endometrial cancer is required. Such a marker is not yet av ailable, although there have been many attempts to find it. In the meantinie, hundreds of thousands of women around the globe avoid hormone replacement therapy under the concern that estrogen treatment causes cancer, though this has never been proven in appropriate experimental studies.
Women are also being exposed to progestin regimens that, on balance, have significant anti-estrogenic, negative effects on estrogen-sensitive SystemIs. Frederick Naftolin, MD, DPhil
